Kyntra Bio (KYNB) analyst forecast and price target
Analyst forecast
Consensus of 5 analyst ratings
Based on 3 analyst targets
Recent analyst ratings
| Firm | Action | Rating | Price target | Date |
|---|---|---|---|---|
| Maxim Group | Initiated Coverage | Buy | $35.00 | Oct 13, 2026 |
| Lake Street | Initiated Coverage | Buy | $41.00 | Sep 17, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $43.00 | Sep 1, 2026 |
| Oppenheimer | Initiated Coverage | Outperform | $35.00 | Jul 7, 2026 |
| Rodman & Renshaw | Initiated Coverage | Buy | $30.00 | Jun 9, 2026 |
| HC Wainwright & Co. | Maintained | Buy | $43.00 | Sep 24, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $43.00 from $10.00 | Aug 7, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | May 13, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Mar 18, 2025 |
| HC Wainwright & Co. | Maintained | Buy | $10.00 | Feb 20, 2025 |
| B of A Securities | Downgraded | Neutral → Underperform | $2.00 from $4.00 | Aug 8, 2023 |
| Goldman Sachs | Maintained | Sell | $2.00 from $16.00 | Jun 27, 2023 |
| Raymond James | Downgraded | Outperform → Market Perform | — | Jun 27, 2023 |
| B of A Securities | Downgraded | Buy → Neutral | $4.00 from $29.00 | Jun 26, 2023 |
| Raymond James | Downgraded | Outperform → Market Perform | — | Jun 26, 2023 |
| Stifel | Downgraded | Buy → Hold | $11.00 from $28.00 | Jun 26, 2023 |
| William Blair | Downgraded | Outperform → Market Perform | — | Jun 26, 2023 |
| Stifel | Upgraded | Hold → Buy | — | Jun 2, 2023 |
| Cowen & Co. | Maintained | Market Perform | $25.00 from $15.00 | Feb 28, 2023 |
| Goldman Sachs | Maintained | Sell | $16.00 from $9.00 | Feb 23, 2023 |
Frequently asked questions
What is the price target for KYNB stock?
The average 12-month analyst price target for Kyntra Bio (KYNB) is $39.67, with a high estimate of $43.00 and a low of $35.00, across 3 analysts.
Is KYNB a buy, sell, or hold?
Analysts covering Kyntra Bio currently average a Buy rating: 4 buy, 1 hold and 0 sell, from 5 analysts. Ratings reflect analyst opinion, not investment advice.
What upside do analysts see for KYNB?
The average price target of $39.67 implies 575.75% upside from the last price of $5.87.
What is the latest analyst rating on KYNB?
On Oct 13, 2026, Maxim Group initiated coverage of Kyntra Bio at Buy with a price target of $35.00.
Analyst ratings and price targets are the opinions of third-party research firms, not of Light Horse Securities. They are estimates about an uncertain future, are frequently wrong, and are neither a recommendation nor a prediction of actual results.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.